title: Monoclonal Antibody Drugs for Systemic Lupus Erythematosus.
abstract: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease which engages most of the immune cells in its development. Various studies concerning the application of antibodies against TNF-α, BlyS, CD20, CD22, IL-6R and complement factors in treatment of SLE have been recently conducted and in spite of the good results reported by some of them, no definite conclusion on their risk-benefit profile can be drawn. The current review summarizes the results obtained in the field and reveals the perspectives for the development of new and more effective strategies for SLE treatment in combination with other immunomodulating drugs.
authors.affiliation: Molecular Medicine Center, Medical University, Sofia, Bulgaria
authors.forename: Zornitsa G
authors.initials: ZG
authors.lastname: Kamenarska
authors.affiliation: Department of Nephrology, Medical University, Sofia, Bulgaria
authors.forename: Maria H
authors.initials: MH
authors.lastname: Hristova
authors.affiliation: Service de Neurologie, Hôpitaux Drome Nord, Romans-sur-Isère, France
authors.forename: Anton I
authors.initials: AI
authors.lastname: Vinkov
authors.affiliation: Department of Dermatology and Venereology, Medical University, Sofia, Bulgaria
authors.forename: Lyubomir A
authors.initials: LA
authors.lastname: Dourmishev
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D000069283:Rituximab / Q000627:therapeutic use; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D051918:Sialic Acid Binding Ig-like Lectin 2; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; C481642:eculizumab